Revenues (Details) - WAINUA (Eplontersen) Collaboration with AstraZeneca [Member] $ in Millions	6 Months Ended	12 Months Ended
	Jun. 30, 2025	Dec. 31, 2021 USD ($) Component PerformanceObligation
Revenues [Abstract]
Upfront payment received		$ 200
Number of material components (in Component) | Component		4
Number of performance obligations (in PerformanceObligation) | PerformanceObligation		1
Transaction price		$ 200
Percentage of costs associated with ongoing global Phase 3 development program paid by AstraZeneca	55.00%